Application of an Autoinduction Strategy to Optimize the Heterologous Production of an Antitumor Bispecific Fusion Protein Based on the TRAIL Receptor-Selective Mutant Variant in Escherichia coli-Reference-Cited by-同舟云学术

Application of an Autoinduction Strategy to Optimize the Heterologous Production of an Antitumor Bispecific Fusion Protein Based on the TRAIL Receptor-Selective Mutant Variant in Escherichia coli

Published:2022-09-12 Issue: Volume: Page:
ISSN:1073-6085
Container-title:Molecular Biotechnology
language:en
Short-container-title:Mol Biotechnol

Author:

Isakova Alina,Artykov Artem,Vorontsova Yekaterina,Dolgikh Dmitry,Kirpichnikov Mikhail,Gasparian Marine,Yagolovich Anne^ORCID

Funder

Russian Science Foundation

Publisher

Springer Science and Business Media LLC

Subject

Molecular Biology,Applied Microbiology and Biotechnology,Biochemistry,Bioengineering,Biotechnology

Link

https://link.springer.com/content/pdf/10.1007/s12033-022-00561-6.pdf

Reference51 articles.

1. Dianat-Moghadam, H., Heidarifard, M., Mahari, A., Shahgolzari, M., Keshavarz, M., Nouri, M., & Amoozgar, Z. (2020). TRAIL in oncology: From recombinant TRAIL to nano- and self-targeted TRAIL-based therapies. Pharmacological Research, 155, 104716. https://doi.org/10.1016/j.phrs.2020.104716

2. Krishna Moorthy, N., Seifert, O., Eisler, S., Weirich, S., Kontermann, R. E., Rehm, M., & Fullstone, G. (2021). Low-level endothelial TRAIL-receptor expression obstructs the CNS-delivery of angiopep-2 functionalised TRAIL-receptor agonists for the treatment of glioblastoma. Molecules, 26(24), 7582. https://doi.org/10.3390/molecules26247582

3. Bremer, E., Samplonius, D. F., van Genne, L., Dijkstra, M. H., Kroesen, B. J., de Leij, L. F. M. H., & Helfrich, W. (2005). Simultaneous inhibition of epidermal growth factor receptor (EGFR) signaling and enhanced activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-mediated apoptosis induction by an scFv:STRAIL fusion protein with specificity for human EGFR. Journal of Biological Chemistry, 280(11), 10025–10033. https://doi.org/10.1074/jbc.M413673200

4. de Bruyn, M., Rybczynska, A. A., Wei, Y., Schwenkert, M., Fey, G. H., Dierckx, R. A., & Bremer, E. (2010). Melanoma-associated chondroitin sulfate proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo. Molecular Cancer, 9(1), 301. https://doi.org/10.1186/1476-4598-9-301

5. Hendriks, D., He, Y., Koopmans, I., Wiersma, V. R., van Ginkel, R. J., Samplonius, D. F., & Bremer, E. (2016). Programmed death ligand 1 (PD-L1)-targeted TRAIL combines PD-L1-mediated checkpoint inhibition with TRAIL-mediated apoptosis induction. OncoImmunology, 5(8), e1202390. https://doi.org/10.1080/2162402X.2016.1202390